Inflammation adversely affects the health of millions of people worldwide, and there is an unmet medical need for better anti-inflammatory drugs. We evaluated the therapeutic interest of mycolactone, a polyketide-derived macrolide produced by Mycobacterium ulcerans. Bacterial production of mycolactone in human skin causes a combination of ulcerative, analgesic, and anti-inflammatory effects. Whereas ulcer formation is mediated by the proapoptotic activity of mycolactone on skin cells via hyperactivation of Wiskott-Aldrich syndrome proteins, analgesia results from neuronal hyperpolarization via signaling through angiotensin II type 2 receptors. Mycolactone also blunts the capacity of immune cells to produce inflammatory mediators by an independent mechanism of protein synthesis blockade. In an attempt to isolate the structural determinants of mycolactone's immunosuppressive activity, we screened a library of synthetic subunits of mycolactone for inhibition of cytokine production by activated T cells. The minimal structure retaining immunosuppressive activity was a truncated version of mycolactone, missing one of the two core-branched polyketide chains. This compound inhibited the inflammatory cytokine responses of human primary cells at noncytotoxic doses and bound to angiotensin II type 2 receptors comparably to mycolactone in vitro. Notably, it was considerably less toxic than mycolactone in human primary dermal fibroblasts modeling ulcerative activity. In mouse models of human diseases, it conferred systemic protection against chronic skin inflammation and inflammatory pain, with no apparent side effects. In addition to establishing the anti-inflammatory potency of mycolactone in vivo, our study therefore highlights the translational potential of mycolactone core-derived structures as prospective immunosuppressants.
INTRODUCTION
Whether mycolactone, the major virulence factor of Mycobacterium ulcerans, affects the systemic generation of inflammatory mediators in infected hosts remains unclear (1) (2) (3) . Mycolactone production by bacteria infecting the skin provokes focal lesions called Buruli ulcers (BU) that are marked by an association of tissue necrosis, local analgesia, and defective inflammation (4) . We reported previously that mycolactone-driven destruction of cutaneous tissues proceeds through hyperactivation of N-WASP, a protein controlling the junctional organization and coordinated migration of epidermal cells (5) . Recently, mycolactone was shown to inhibit pain perception by binding to angiotensin II type 2 receptors (AT 2 Rs) on neurons, leading to potassiumdependent hyperpolarization (6) .
In addition to a lack of inflammatory infiltrates at the level of skin lesions (7), patients with BU display systemic alterations in their cellular immune responses, evidenced by an impaired capacity of T cells to produce cytokines ex vivo upon stimulation with mitogenic agents (8) (9) (10) . Contrary to wild-type strains, mycolactone-deficient mutants of M. ulcerans do not impair the capacity of T cells to produce interleukin-2 (IL-2) in animal models, showing that mycolactone is the cause of these cellular response defects (11) . In vitro, nanomolar concentrations of mycolactone efficiently blocked the functional maturation of dendritic cells (12) and cytokine production by activated lymphocytes, monocytes, macrophages, and epithelial cells (13) (14) (15) (16) (17) . Mycolactone also down-regulated the expression of L-selectin on naïve T cells, profoundly affecting the lymphocyte homing and expansion upon antigenic stimulation in vivo (18) . Although the molecular receptor mediating these effects remains to be identified, there is recent evidence showing that mycolactone operates by an original mechanism of posttranscriptional blockade of protein synthesis, selectively affecting membrane and secreted proteins (17) .
Following release by bacterial infection of the skin, or upon subcutaneous injection, mycolactone diffuses into the peripheral blood and reaches lymphoid organs (11, 19) . This diffusion capacity, combined with potent immunosuppressive and analgesic properties, makes mycolactone a drug candidate for the treatment of inflammatory disorders. Its development for clinical use nevertheless faces two major challenges. First, the chemical synthesis of this complex natural product is a costly, multistep process (1, (20) (21) (22) , which challenges bulk industrial production. Second, whether mycolactone can be engineered to dissociate immunosuppression and analgesia from cytotoxicity is currently unknown (23) (24) (25) . Here, we screened a large panel of structural variants of mycolactone in biochemical and cellular assays reflecting its biological activities. We identified a simplified and detoxified version of mycolactone that bound to analgesia-mediating receptors comparably to the natural product, and mimicked its inhibitory action on inflammatory cytokine production. This synthetic compound efficiently protected mice against chronic skin inflammation and inflammatory pain, establishing the therapeutic potential of this mycolactone derivative.
RESULTS
Immunomodulatory and cytopathic features of mycolactone can be partially dissociated Mycolactone produced by M. ulcerans is composed of three structural modules: a 12-membered lactone ring and two polyketide-derived chains that are branched to the core in the north and south positions (Fig. 1) . Bacteria produce a mixture of cis/trans isomers designated A/B. To investigate the contribution of each subunit of mycolactone A/B to biological activity, we used synthetic compounds corresponding to the lactone core and fatty acyl chains assembled in diverse combinations, and harboring variations in the structure and hydroxylation of the polyketide chains (20, 23) (Fig. 1 ). Variants were compared to mycolactone for their capacity to block the activation-induced production of IL-2 by Jurkat cells, using the half maximal inhibitory concentration (IC 50 ) as a comparator ( Fig. 2A and fig. S1 ). In this T cell model, mycolactone dose-dependently inhibited the production of IL-2 upon cell stimulation with phorbol 12-myristate 13-acetate (PMA) and ionomycin (IO) with an IC 50 of 40 nM (13) . Variants were also assessed for their cytopathic activity in the human epithelial cell line HeLa, a model that is highly susceptible to mycolactonemediated anoïkis (5) . Here, we compared variants for their capacity to induce cell detachment after 48 hours, conditions in which mycolactone induces >80% cytotoxicity ( Fig. 2A and fig. S1 ). Figure 2B plots the aforementioned parameters of immunomodulation and cytotoxicity of each variant.
Notably, all variants were less active than mycolactone, indicating that each structural module of the natural molecule has a biological role (Fig. 2B and fig.  S1 ). Compared to mycolactone, immunomodulatory activity was best retained in compounds 32b, 30, 5r, and 5b (IC 50 of 1.5 mM), in which the north chain is missing (5b, 5r, and 30) or replaced by a 4-alkyl-1,2,3-triazole (32b). Among them, saturation of the lactone core (30) or substitution of the C1′-C7′ sector of the south chain with a cinnamyl (5r) did not alter activity. Of note, 32b, 30, and 5r were more cytotoxic than 5b, showing that cytotoxicity and immunosuppressive activity can be, at least partially, dissociated. A second group of mycolactone analogs displaying IC 50 in the 2.2 to 3.4 mM range encompassed derivatives with inverted and/or deoxy C12′, C13′, and C15′ stereocenters. In concordance with previous reports (24) , a significant loss in immunosuppressive and cytotoxic activity was observed when the hydroxyl group in position C12′ was suppressed (5j). Likewise, modification of the C1′-C5′ sector of the southern fragment by introduction of a benzoyl motif was also detrimental to activity (5q). A last group of nine analogs showed no detectable inhibitory activity in the IL-2 assay, under the tested conditions (IC 50 ≥ 4 mM). Their lack of reactivity indicated that shortening the polyketide chain and removing more than one of three hydroxyl groups in the C12′-C13′-C15′ sector has a dramatic impact on immunosuppressive activity. Intriguingly, variant 4b corresponding to C8-desmethyl mycolactone A/B fell in this category, suggesting that intramolecular interactions between the northern chain and lactone core may limit reactivity. Overall, this study showed that the structural requirements for cytotoxic and immunosuppressive activities do not strictly overlap. The 5b variant, corresponding to mycolactone without north chain and core C8-methyl, displayed an optimal ratio of immune suppression to cytotoxicity, prompting us to examine its biological properties in further detail.
5b suppresses inflammatory responses in human primary cells To gain insight into the translational potential of 5b, we next assessed its impact on the viability and functional biology of key subsets of human inflammatory cells. Polymorphonuclear neutrophils (PMN) dominate the early stages of inflammation, and activated PMN sustain inflammatory responses via the production of cytokines like tumor necrosis factor-a (TNF-a) (26) . PMN isolated from venous blood of healthy donors were incubated for up to 24 hours with mycolactone or 5b, before activation with PMA. Although the viability of PMN declined in culture, we did not observed increased mortality in the presence of mycolactone or 5b, irrespective of the cell activation state ( fig. S2 ). Notably, exposure to mycolactone, and 5b to a lower extent, efficiently blocked the ability of PMN to release TNF-a upon activation (Fig. 3A) . Production of TNF-a by lipopolysaccharide (LPS)-stimulated monocyte-derived macrophages (MDM) was also potently inhibited by preincubation with mycolactone or 5b, without evidence of cell mortality (Fig. 3B ). Of note, prolonged exposure (>48 hours) of MDM to immunomodulatory concentrations of mycolactone or 5b eventually altered cell viability (Fig. 3C ). In contrast, the viability of CD4 + T cells was not altered by exposure to mycolactone or 5b for up to 48 hours ( fig. S3 ). Their PMA/IO-induced production of IL-2 and interferon-g (IFN-g) was markedly inhibited by preincubation with mycolactone or 5b (as shown for IL-2 in Fig. 3D ).
Mycolactone binding to AT 2 R, evidenced by competition with an AT 2 R agonist in vitro, was previously reported to mediate analgesia (6) . We found that mycolactone and 5b displaced the AT 2 R agonist with comparable efficacy (Fig. 3E ). Finally, because BU formation involves primarily the destruction of human dermis by mycolactone, we used primary human dermal fibroblasts (HDF) to model the potential ulcerative properties of 5b in vivo. As shown in Fig. 3F , HDF displayed a high susceptibility to mycolactone-mediated killing, with a 50% loss in cell viability upon incubation with nanomolar concentrations of mycolactone for 48 hours. In support for safe use in humans, the cytotoxicity of variant 5b was markedly lower. Table 1 summarizes the IC 50 measured for mycolactone and 5b in the biochemical and cellular assays described above. They show that 5b conserved the biological activities of mycolactone to different degrees. Capacity to bind AT 2 R expressed on recombinant cells was largely preserved in 5b, suggesting that full and truncated molecules may have comparable analgesic effects in vivo. Variant 5b also mimicked mycolactone for inhibition of cytokine production by PMN, MDM, and CD4 + T cells, with a 162-to 320-fold reduction in activity. Antiinflammatory effects were always observed in the absence of cytotoxicity. The viability of PMN and CD4 + T cells was not altered by exposure to mycolactone or 5b, under the conditions tested. In the mycolactone-susceptible MDM and HDF, 5b was 514 and 1910 times less toxic than mycolactone, respectively. In addition, to be synthetically simpler than the mycobacterial factor, 5b may therefore have a broader therapeutic window.
Mycolactone and 5b both protect against chronic skin inflammation We used the PMA mouse model of chronic skin inflammation (27, 28) to evaluate the anti-inflammatory potential of mycolactone and 5b in vivo. A dose of 0.5 mg/kg was chosen for mycolactone, which is the maximum concentration allowing injections at >2-day intervals without induction of skin ulceration. Because it was less potent than mycolactone in cellular assays, we administered 5b at 5 mg/kg, corresponding to the maximum solubility of the 10× injection solution in phosphatebuffered saline (PBS). Repeated applications of PMA on the back of hairless mice (from day 1 to day 8 and then at day 10 and day 12; Fig. 4A ) triggered a visible inflammation of dorsal skin (Fig. 4B) , characterized by cell infiltrates in dermis and epidermis, vascular dilation, and tissue thickening (Fig. 4, C and D) . Notably, intraperitoneal injections of mycolactone at days 0, 4, 8, and 12, and to a lower extent 5b, significantly reduced both macroscopic and microscopic signs of inflammation (Fig. 4 , B and C, and table S1). Of note, the protection afforded by 5b was more similar to that of mycolactone in skin areas situated at the periphery of the site of PMA application ( fig. S4 ). In histopathological scoring of skin inflammation, 5b more closely resembled mycolactone's anti-inflammatory effects in the dermis ( fig. S4 ). In this tissue, a marked reduction in the recruitment of both acute and chronic inflammatory cells, fibrosis, and vascular damage could be observed in both mycolactone-and 5b-treated mice. Systemic mycolactone and 5b relieve local inflammatory pain Antinociceptive activity of mycolactone was recently demonstrated by injection of mycolactone in mouse footpads and local assessment of pain sensitivity to a thermal stimulus (6) . Having shown that mycolactone and 5b exert anti-inflammatory effects at a distance from the injection site, we investigated whether systemic delivery of the molecules induced local control of pain. We used the formalin assay in mice because it is considered a reliable model of nociception that allows to discriminate inflammatory and noninflammatory pain (29) . Injection of a formalin solution into mouse hindpaws induces two distinct periods of stereotypical licking and biting behaviors. The first 5 min reflects a direct effect on nociceptors (acute pain), whereas the second phase, lasting from 10 to 40 min, involves primarily inflammatory processes (Fig. 5A ). Figure 5B shows that intraperitoneal injection of mycolactone (0.5 mg/kg) or 5b (5 mg/kg) 1 hour before formalin injection had no effect on the early phase of the assay. In contrast, both molecules were antinociceptive in the late phase (Fig. 5C ), demonstrating their systemic and selective effect against inflammatory pain. As a centrally acting analgesic, morphine was antinociceptive in both phases.
DISCUSSION
Pathogenic species of mycobacteria have evolved to produce original polyketide synthase products with virulence and immunomodulatory properties (30) . This is well exemplified by M. ulcerans, which differs from its Mycobacterium marinum ancestor essentially by the presence of giant plasmid-encoded polyketide synthases producing mycolactone (31, 32) . Using cellular models, we and others have shown over the past few years that in addition to causing the formation of painless ulcers, mycolactone is a natural immunosuppressor operating via a novel mechanism of action (12-15, 17, 18, 33) . Here, we demonstrate that mycolactone can be used therapeutically to suppress inflammatory responses. In agreement with cellular assays demonstrating its inhibitory activity on cytokine production by activated neutrophils, macrophages, and T cells, systematically delivered mycolactone was effective in limiting inflammation in mouse models of skin inflammation and rheumatoid arthritis ( fig. S5 ). Mycolactone was recently reported to reduce pain locally by stimulating the angiotensin/cyclooxygenase-1/prostaglandin E 2 (PGE 2 ) pathway in neurons and potentially other AT 2 R-expressing cells such as macrophages or fibroblasts (34) . Here, we showed that mycolactone is effective in controlling inflammatory pain generated distantly. Whether this analgesic effect operates via AT 2 Rs, suppression of inflammatory cytokine production, or both mechanisms will require more investigations. Our observation that mycolactone selectively reduces inflammatory pain in the formalin test in mice does not allow us to discriminate between one or the other of these mechanisms because PGE 2 and cytokine release both develop during the late phase. However, the high potency of mycolactone and 5b in suppressing inflammatory cytokine production, including proalgesic TNF-a (Fig. 3) , strongly suggests that this immunomodulatory activity is at play. The identification of the yet mysterious molecular receptor by which mycolactone blocks cytokine production will be a profitable area of research because it will allow to dissect further the mechanisms of its analgesic properties.
Because mycolactone is not easily amenable to large-scale synthesis, we aimed to determine whether its structure could be simplified without loss in biological activity. In vitro and in vivo assays identified the 5b subunit as an alternative to full mycolactone retaining capacity to block cytokine production by neutrophils, macrophages, and lymphocytes, although with less potency. From a clinical perspective, 5b offers several advantages over the natural molecule, in addition to being easier to chemically synthesize. First, its smaller size (572 versus 743 daltons) should allow a better distribution of the product throughout the fluids and tissues of the body. Second, cellular assays showed that 5b retains the desirable (immunomodulatory and AT 2 R binding) properties of mycolactone relatively better than its undesirable (cytotoxic) ones. Accordingly, 5b delivered at 5 mg/kg more than three times at 2-day intervals was not ulcerative in mice. In comparison, injections of mycolactone at this frequency and at 10 times lower concentrations caused skin lesions. The dosage regimen used in the present work to demonstrate the protective efficacy of 5b could therefore be intensified to improve clinical benefit, without inducing side effects. In conclusion, our study provides proof of concept that mycolactone derivatives have a therapeutic potential. It paves the way for future research on mycolactone-inspired molecules for the treatment of inflammatory pain and inflammatory diseases.
MATERIALS AND METHODS

Study design
This study was designed to evaluate the potential of mycolactone and a series of truncated synthetic variants of this natural product as clinical immunosuppressants. A first screen of the molecules was performed in human cell lines, leading to the identification of a lead candidate retaining the immunosuppressive properties of mycolactone relatively better than its cytopathic activity. The translational potential of mycolactone and synthetic surrogate was then evaluated in functionally relevant subsets of human primary cells (from at least three donors) and mouse models of inflammatory disorders (PMA-induced skin inflammation and formalin-induced pain). Mean clinical scores of inflammation were determined in mice randomly grouped according to weight in a double-blind manner. Outliers were defined as at least 1.5 × interquartile range (IQR) greater than the upper quartile, or 1.5 × IQR less than the lower quartile (IQR = upper quartile value − lower quartile value). There was no outlier in the skin inflammation study. Those detected in the formalin-induced pain assay were excluded from the statistical analysis.
Natural mycolactone and synthetic variants Mycolactone was purified from M. ulcerans bacterial pellets (strain 1615, ATCC 35840) and then quantified by spectrophotometry (3, 35) . Modular variants of mycolactone were synthesized as described (20, 23) . Stock solutions of mycolactone and variants were prepared in dimethyl sulfoxide, and then diluted 1000× in culture medium for cellular assays or 10× in PBS before injection in animals. In all cases, controls exposed to the same volume of vehicle were included.
Cell cultures
HeLa cells (ATCC CCL-2), Jurkat E6.1 T cells (ATCC TIB-152), and adult HDF (Life Technologies, C-013-5C) were cultured in RPMI Glutamax (Life Technologies), supplemented with 10% heat-inactivated fetal calf serum (Invitrogen) and penicillin/streptomycin (100 U/ml, 100 mg/ml). Human primary T cells were isolated from blood donors by Ficoll density gradient centrifugation and CD4 + T cell purification by negative depletion (Miltenyi Biotec). Human primary macrophages were obtained from peripheral blood-derived monocytes, isolated by adhesion to tissue culture plasticware, and cultured with human granulocytemacrophage colony-stimulating factor (10 ng/ml; PeproTech) for 7 to 12 days. For PMN isolation, blood samples from normal human donors drawn in EDTA were fractionated by density centrifugation on Lympholyte-poly separation medium (Cedarlane Labs) as described (36) , and PMN were maintained in X-Vivo 15 medium (BioWhittaker).
Assays of cytotoxic and immunosuppressive activity Detachment-induced cell death studies used HeLa cells seeded in 96-well plates (10 4 cells per well) and incubated with variants or mycolactone (16 mM), or vehicle as control, for 48 hours before enumeration of cells excluding trypan blue. The differential effects of mycolactone and 5b on the viability of human primary HDF, MDM, and CD4 + T lymphocytes were measured with the methyl-thiazolyl-tetrazolium (MTT) reduction assay. We used phosphatidylserine exposure (annexin V staining) and loss of membrane integrity (propidium iodide staining) to further assess the induction of apoptosis in human primary CD4 + T lymphocytes and PMN. Immunosuppressive activity on T cells was measured through the inhibition of IL-2 and IFN-g production by Jurkat or human primary CD4 + T lymphocytes incubated with mycolactone or 5b for 1 hour before 16 hours of activation with PMA/IO, as described (13) . Human primary PMN were incubated with mycolactone or 5b for 1 to 24 hours before 2 hours of activation with PMA (100 ng/ml). Human primary MDM were incubated with mycolactone or 5b for 1 hour before 16 hours of activation with LPS (1 mg/ml). Supernatants of PMN and MDM were then collected to quantify TNF-a release using enzyme-linked immunosorbent assay. Mean percentages of inhibition of viability or cytokine release were calculated in duplicates, relative to vehicle controls. 
PMA-induced skin inflammation
Hairless Skh-1 mice were randomized into four groups of six mice each after the acclimatization period. Inflammation was induced by daily application of 20 mg of PMA on dorsal skin, from day 1 to day 8 and then at day 10 and day 12, as previously described (27) . Mycolactone (0.5 mg/kg), 5b (5 mg/kg), or vehicle as control was injected intraperitoneally at days 0, 4, 8, and 12 . Administration of mycolactone or 5b with this regimen did not induce tissue damage at the site of injection. Inflammation of mouse dorsal skin was scored daily by clinical examination of the animals and by measuring the index of cutaneous inflammation (0, none or no further skin inflammation; 1, weak skin inflammation; 2, moderate skin inflammation; 3, important skin inflammation; 4, very important skin inflammation) in three areas: the site of PMA application, the periphery of this site, and the rest of the mouse dorsum. A global score of the external aspect of cutaneous inflammation was then calculated, corresponding to the sum of these three measures (table S1). Mice were sacrificed at day 14, and photos of the mouse dorsum were taken. Biopsies were harvested at the different sites, fixed in Roti-Histofix 4% solution (Carl Roth) for histological examination at different depths of 6 to 10 cross sections (5 mm thick), and stained with hematoxylin and eosin. Inflammation was scored in the epidermis, dermis, and hypodermis on the basis of tissue-specific histopathological parameters. A global histopathological score was then calculated (0 to 44), corresponding to the sum of these measures (table S1).
Formalin-induced pain
The analgesic properties of mycolactone and 5b were tested in the formalin-induced paw licking test (37, 38) in OF1 mice. Briefly, mice were randomized into five groups of eight mice each after the acclimatization period. Mycolactone and 5b were administered intraperitoneally at 0.5 and 5 mg/kg, respectively, 60 min before the subcutaneous injection of the right hindpaw with 10 ml of a 5% formalin solution. Two negative control groups, injected with PBS (neutral) or ethanol vehicle (vehicle), were tested under the same conditions. A group injected with morphine (3 mg/kg) 15 min before formalin injection was used as a positive reference. The duration of formalin-injected paw licking and the number of body tremors during the early phase (0 to 5 min) and the late phase (10 to 40 min) were recorded.
Statistical analysis
Data of the animal studies were analyzed with the Kruskal-Wallis test followed in case of significance (P < 0.05) by the Mann-Whitney U test (two-sided) to compare each treated group with its vehicle control. Statistical analyses were performed with StatView 5 software (SAS Institute Inc.), and values of P ≤ 0.05 were considered significant. The Prism software (5.0d) was used for graphical representation.
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